Published March 17, 2021 | Version v1
Journal article Open

Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD—Disease Outcome and Response to Therapy

Authors/Creators

  • 1. University Hospitals Leuven Department of Gastroenterology and Hepatology, KU Leuven, Leuven, Belgium
  • 2. Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust, Cambridge, UK
  • 3. Integrative Genomics Lab, Center for Cooperative Research in Biosciences [CIC bioGUNE], Basque Research and Technology Alliance [BRTA], Derio, Spain
  • 4. Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, UK
  • 5. Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine, St Louis, MO, USA
  • 6. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • 7. Multiple

Description

Inflammatory bowel diseases [IBD] are a heterogeneous spectrum with two extreme phenotypes,
Crohn’s disease [CD] and ulcerative colitis [UC], which both represent numerous phenotypical
variations. Hence, we should no longer approach all IBD patients similarly, but rather aim to rethink
clinical classifications and modify treatment algorithms to usher in a new era of precision medicine
in IBD. This scientific ECCO workshop aims to provide a state-of-the-art overview on prognostic and
predictive markers, shed light on key questions in biomarker development, propose best practices
in IBD biomarker development [including trial design], and discuss the potential for multi-omic
data integration to help drive further advances to make precision medicine a reality in IBD.

Notes

We would like to acknowledge academic medical illustrator Jill Gregory, CMI, FAMI, for assistance with figure design.

Files

MarigortaLab_2021_JCC_7thWorkshopECCOprecisionMedicine.pdf

Files (586.7 kB)